L Trevor Young

List of Publications by Year
in descending order

131 papers	12,344 citations	26630 56 h-index	24982 109 g-index
132 all docs	132 docs citations	132 times ranked	10063 citing authors

#	Article	IF	Citations
1	Course of illness, hippocampal function, and hippocampal volume in major depression. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 1387-1392.	7.1	854
2	Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013. Bipolar Disorders, 2013, 15, 1-44.	1.9	740
3	Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2009. Bipolar Disorders, 2009, 11, 225-255.	1.9	545
4	Decreased levels of glutathione, the major brain antioxidant, in post-mortem prefrontal cortex from patients with psychiatric disorders. International Journal of Neuropsychopharmacology, 2011, 14, 123-130.	2.1	462
5	Oxidative stress markers in bipolar disorder: A meta-analysis. Journal of Affective Disorders, 2008, 111, 135-144.	4.1	442
6	Mitochondrial Complex I Activity and Oxidative Damage to Mitochondrial Proteins in the Prefrontal Cortex of Patients With Bipolar Disorder. Archives of General Psychiatry, 2010, 67, 360.	12.3	382
7	Brain-derived neurotrophic factor and inflammatory markers in patients with early- vs. late-stage bipolar disorder. International Journal of Neuropsychopharmacology, 2009, 12, 447.	2.1	343
8	Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: consensus and controversies. Bipolar Disorders, 2005, 7, 5-69.	1.9	321
9	Genetic variants associated with response to lithium treatment in bipolar disorder: a genome-wide association study. Lancet, The, 2016, 387, 1085-1093.	13.7	306
10	A review of psychosocial outcome in patients with bipolar disorder. Acta Psychiatrica Scandinavica, 2001, 103, 163-170.	4.5	286
11	Increased temporal cortex CREB concentrations and antidepressant treatment in major depression. Lancet, The, 1998, 352, 1754-1755.	13.7	270
12	An updated meta-analysis of oxidative stress markers in bipolar disorder. Psychiatry Research, 2014, 218, 61-68.	3.3	266
13	Increased oxidative stress in the anterior cingulate cortex of subjects with bipolar disorder and schizophrenia. Bipolar Disorders, 2009, 11, 523-529.	1.9	217
14	Double-Blind Comparison of Addition of a Second Mood Stabilizer Versus an Antidepressant to an Initial Mood Stabilizer for Treatment of Patients With Bipolar Depression. American Journal of Psychiatry, 2000, 157, 124-126.	7.2	207
15	Biomarkers in bipolar disorder: A positional paper from the International Society for Bipolar Disorders Biomarkers Task Force. Australian and New Zealand Journal of Psychiatry, 2013, 47, 321-332.	2.3	193
16	Newer Antiepileptic Drugs in Bipolar Disorder. CNS Drugs, 2002, 16, 549-562.	5.9	188
17	Bilateral Hippocampal Volume Increase in Patients with Bipolar Disorder and Short-term Lithium Treatment. Neuropsychopharmacology, 2008, 33, 361-367.	5.4	187
18	Bilateral hippocampal volume increases after long-term lithium treatment in patients with bipolar disorder: a longitudinal MRI study. Psychopharmacology, 2007, 195, 357-367.	3.1	186

#	Article	IF	Citations
19	Chronic Treatment with Mood Stabilizers Lithium and Valproate Prevents Excitotoxicity by Inhibiting Oxidative Stress in Rat Cerebral Cortical Cells. Biological Psychiatry, 2005, 58, 879-884.	1.3	185
20	Brain glutamate levels measured by magnetic resonance spectroscopy in patients with bipolar disorder: a metaâ€analysis. Bipolar Disorders, 2012, 14, 478-487.	1.9	184
21	Stress-induced structural remodeling in hippocampus: Prevention by lithium treatment. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 3973-3978.	7.1	179
22	Cerebral Cortex Gs? Protein Levels and Forskolin-Stimulated Cyclic AMP Formation Are Increased in Bipolar Affective Disorder. Journal of Neurochemistry, 1993, 61, 890-898.	3.9	161
23	Anxious and non-anxious bipolar disorder. Journal of Affective Disorders, 1993, 29, 49-52.	4.1	159
24	CNS signal transduction in the pathophysiology and pharmacotherapy of affective disorders and schizophrenia. Synapse, 1993, 13, 278-293.	1.2	153
25	Downregulation in components of the mitochondrial electron transport chain in the postmortem frontal cortex of subjects with bipolar disorder. Journal of Psychiatry and Neuroscience, 2006, 31, 189-96.	2.4	151
26	Relationship between the five-factor model of personality and unipolar, bipolar and schizophrenic patients. Psychiatry Research, 1997, 70, 83-94.	3.3	149
27	3-Nitrotyrosine and glutathione antioxidant system in patients in the early and late stages of bipolar disorder. Journal of Psychiatry and Neuroscience, 2009, 34, 263-71.	2.4	140
28	The International Consortium on Lithium Genetics (ConLiGen): An Initiative by the NIMH and IGSLI to Study the Genetic Basis of Response to Lithium Treatment. Neuropsychobiology, 2010, 62, 72-78.	1.9	134
29	Oxidative damage to RNA but not DNA in the hippocampus of patients with major mental illness. Journal of Psychiatry and Neuroscience, 2010, 35, 296-302.	2.4	132
30	Subsyndromal symptoms assessed in longitudinal, prospective followâ€up of a cohort of patients with bipolar disorder. Bipolar Disorders, 2003, 5, 349-355.	1.9	131
31	Effect of number of episodes on wellbeing and functioning of patients with bipolar disorder. Acta Psychiatrica Scandinavica, 2000, 101, 374-381.	4.5	130
32	Effects of endogenous dopamine on kinetics of [3H]N-methylspiperone and [3H]raclopride binding in the rat brain. Synapse, 1991, 9, 188-194.	1.2	126
33	Acute and chronic restraint stress alter the incidence of social conflict in male rats. Hormones and Behavior, 2003, 43, 205-213.	2.1	123
34	G Protein-Coupled Cyclic AMP Signaling in Postmortem Brain of Subjects with Mood Disorders. Journal of Neurochemistry, 2001, 73, 1121-1126.	3.9	122
35	Brain Structural Signature of Familial Predisposition for Bipolar Disorder: Replicable Evidence For Involvement of the Right Inferior Frontal Gyrus. Biological Psychiatry, 2013, 73, 144-152.	1.3	118
36	Quantification of Neuroreceptors in the Living Human Brain: IV. Effect of Aging and Elevations of D2-Like Receptors in Schizophrenia and Bipolar Illness. Journal of Cerebral Blood Flow and Metabolism, 1997, 17, 331-342.	4.3	117

#	Article	IF	Citations
37	Risk and Resilience Markers in Bipolar Disorder: Brain Responses to Emotional Challenge in Bipolar Patients and Their Healthy Siblings. American Journal of Psychiatry, 2006, 163, 257-264.	7.2	113
38	A Randomized Controlled Trial of Psychoeducation or Cognitive-Behavioral Therapy in Bipolar Disorder. Journal of Clinical Psychiatry, 2012, 73, 803-810.	2.2	111
39	The Phosphoinositide Signal Transduction System Is Impaired in Bipolar Affective Disorder Brain. Journal of Neurochemistry, 1996, 66, 2402-2409.	3.9	110
40	Nod-like receptor pyrin containing 3 (NLRP3) in the post-mortem frontal cortex from patients with bipolar disorder: A potential mediator between mitochondria and immune-activation. Journal of Psychiatric Research, 2016, 72, 43-50.	3.1	104
41	Hippocampal volumes in bipolar disorders: opposing effects of illness burden and lithium treatment. Bipolar Disorders, 2012, 14, 261-270.	1.9	99
42	Reduced [³H]Cyclic AMP Binding in Postmortem Brain from Subjects with Bipolar Affective Disorder. Journal of Neurochemistry, 1997, 68, 297-304.	3.9	94
43	Neuropathological relationship between major depression and dementia: A hypothetical model and review. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2016, 67, 51-57.	4.8	89
44	Gene expression differences in bipolar disorder revealed by cDNA array analysis of post-mortem frontal cortex. Journal of Neurochemistry, 2008, 79, 826-834.	3.9	87
45	Prefrontal cortex glutathione S-transferase levels in patients with bipolar disorder, major depression and schizophrenia. International Journal of Neuropsychopharmacology, 2011, 14, 1069-1074.	2.1	84
46	Mood stabilizing drug lithium increases expression of endoplasmic reticulum stress proteins in primary cultured rat cerebral cortical cells. Life Sciences, 2006, 78, 1317-1323.	4.3	81
47	Lithium response and genetic variation in the CREB family of genes. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2008, 147B, 500-504.	1.7	80
48	Number of manic episodes is associated with elevated DNA oxidation in bipolar I disorder. International Journal of Neuropsychopharmacology, 2013, 16, 1505-1512.	2.1	73
49	Regulation of ER stress proteins by valproate: therapeutic implications. Bipolar Disorders, 2002, 4, 145-151.	1.9	69
50	Toward Clinically Applicable Biomarkers in Bipolar Disorder: Focus on BDNF, Inflammatory Markers, and Endothelial Function. Current Psychiatry Reports, 2013, 15, 425.	4.5	66
51	The Neurobiology of Bipolar Disorder: Focus on Signal Transduction Pathways and the Regulation of Gene Expression. Canadian Journal of Psychiatry, 2002, 47, 135-148.	1.9	65
52	Glutathione Sâ€transferase is a novel target for mood stabilizing drugs in primary cultured neurons. Journal of Neurochemistry, 2004, 88, 1477-1484.	3.9	65
53	Bipolar II Disorder: Symptoms, Course, and Response to Treatment. Psychiatric Services, 2001, 52, 358-361.	2.0	63
54	A Fresh Look at Complex I in Microarray Data: Clues to Understanding Disease-Specific Mitochondrial Alterations in Bipolar Disorder. Biological Psychiatry, 2013, 73, e4-e5.	1.3	62

#	Article	IF	Citations
55	Decreased global methylation in patients with bipolar disorder who respond to lithium. International Journal of Neuropsychopharmacology, 2014, 17, 561-569.	2.1	59
56	The neurobiology of bipolar disorder: identifying targets for specific agents and synergies for combination treatment. International Journal of Neuropsychopharmacology, 2014, 17, 1039-1052.	2.1	58
57	Increased GÎ±q/11 immunoreactivity in postmortem occipital cortex from patients with bipolar affective disorder. Biological Psychiatry, 1997, 41, 649-656.	1.3	56
58	Identification of Lithium-Regulated Genes in Cultured Lymphoblasts of Lithium Responsive Subjects with Bipolar Disorder. Neuropsychopharmacology, 2004, 29, 799-804.	5.4	56
59	Investigating responders to lithium prophylaxis as a strategy for mapping susceptibility genes for bipolar disorder. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2005, 29, 1038-1045.	4.8	56
60	Maturational and aging effects on guanine nucleotide binding protein immunoreactivity in human brain. Developmental Brain Research, 1991, 61, 243-248.	1.7	53
61	A twoâ€illness model of bipolar disorder 1. Bipolar Disorders, 1999, 1, 25-30.	1.9	51
62	Regulation of GAP-43 expression by chronic desipramine treatment in rat cultured hippocampal cells. Biological Psychiatry, 2003, 53, 530-537.	1.3	50
63	Amygdala cyclic adenosine monophosphate response element binding protein phosphorylation in patients with mood disorders: effects of diagnosis, suicide, and drug treatment. Biological Psychiatry, 2004, 55, 570-577.	1.3	50
64	Oxidation and nitration in dopaminergic areas of the prefrontal cortex from patients with bipolar disorder and schizophrenia. Journal of Psychiatry and Neuroscience, 2014, 39, 276-285.	2.4	48
65	Neuron somal size is decreased in the lateral amygdalar nucleus of subjects with bipolar disorder. Journal of Psychiatry and Neuroscience, 2007, 32, 203-10.	2.4	48
66	Implication of synapse-related genes in bipolar disorder by linkage and gene expression analyses. International Journal of Neuropsychopharmacology, 2010, 13, 1397-1410.	2.1	47
67	Gabapentin as an adjunctive treatment in bipolar disorder. Journal of Affective Disorders, 1999, 55, 73-77.	4.1	46
68	Accelerated age-related decrease in brain-derived neurotrophic factor levels in bipolar disorder. International Journal of Neuropsychopharmacology, 2009, 12, 137.	2.1	46
69	Increased hippocampal supragranular Timm staining in subjects with bipolar disorder. NeuroReport, 2000, 11, 3775-3778.	1.2	41
70	Psychiatric Consultation in the Eastern Canadian Arctic: II. Referral Patterns, Diagnoses and Treatment. Canadian Journal of Psychiatry, 1993, 38, 28-31.	1.9	38
71	Longitudinal outcome in patients with bipolar disorder assessed by life-charting is influenced by DSM-IV personality disorder symptoms. Bipolar Disorders, 2003, 5, 14-21.	1.9	38
72	Association of peripheral inflammation with body mass index and depressive relapse in bipolar disorder. Psychoneuroendocrinology, 2016, 65, 76-83.	2.7	37

#	Article	IF	Citations
73	Transgender health in medical education. Bulletin of the World Health Organization, 2021, 99, 296-303.	3.3	36
74	Immunoreactivity of 43kDa growth-associated protein is decreased in post mortem hippocampus of bipolar disorder and schizophrenia. Neuroscience Letters, 2007, 411, 123-127.	2.1	34
75	Oxidative Stress in Older Patients with Bipolar Disorder. American Journal of Geriatric Psychiatry, 2015, 23, 314-319.	1.2	34
76	Lithium reduces the effects of rotenone-induced complex I dysfunction on DNA methylation and hydroxymethylation in rat cortical primary neurons. Psychopharmacology, 2014, 231, 4189-4198.	3.1	33
77	CACNA1C rs1006737 genotype and bipolar disorder: Focus on intermediate phenotypes and cardiovascular comorbidity. Neuroscience and Biobehavioral Reviews, 2015, 55, 198-210.	6.1	33
78	Bipolar Disorder as a Mitochondrial Disease. Biological Psychiatry, 2018, 83, 720-721.	1.3	33
79	Is bipolar disorder a mitochondrial disease?. Journal of Psychiatry and Neuroscience, 2007, 32, 160-1.	2.4	33
80	Decreased expression of insulin-like growth factor binding protein 2 in the prefrontal cortex of subjects with bipolar disorder and its regulation by lithium treatment. Brain Research, 2007, 1147, 213-217.	2.2	32
81	Previous mood state predicts response and switch rates in patients with bipolar depression. Acta Psychiatrica Scandinavica, 2002, 105, 414-418.	4.5	30
82	Mood stabilizer lithium inhibits amphetamine-increased 4-hydroxynonenal-protein adducts in rat frontal cortex. International Journal of Neuropsychopharmacology, 2012, 15, 1275-1285.	2.1	30
83	Bipolar II: Not so different when coâ€morbidity excluded. Depression, 1995, 3, 154-156.	0.6	29
84	Lamotrigine Increases Gene Expression of GABA-A Receptor Î²3 Subunit in Primary Cultured Rat Hippocampus Cells. Neuropsychopharmacology, 2002, 26, 415-421.	5.4	29
85	Immunological and neurotrophic markers of risk status and illness development in high-risk youth: understanding the neurobiological underpinnings of bipolar disorder. International Journal of Bipolar Disorders, 2014, 2, 29.	2.2	29
86	BDNF protein levels are decreased in transformed lymphoblasts from lithium-responsive patients with bipolar disorder. Journal of Psychiatry and Neuroscience, 2008, 33, 449-53.	2.4	29
87	Analysis of the Influence of microRNAs in Lithium Response in Bipolar Disorder. Frontiers in Psychiatry, 2018, 9, 207.	2.6	28
88	Platelet Protein Kinase C alpha Levels in Drug-Free and Lithium-Treated Subjects with Bipolar Disorder. Neuropsychobiology, 1999, 40, 63-66.	1.9	27
89	The neurobiology of treatment response to antidepressants and mood stabilizing medications. Journal of Psychiatry and Neuroscience, 2002, 27, 260-5.	2.4	27
90	Stimulatory G-protein Î±-subunit mRNA levels are not increased in autopsied cerebral cortex from patients with bipolar disorder. Molecular Brain Research, 1996, 42, 45-50.	2.3	25

#	Article	IF	Citations
91	Identification of mood stabilizer-regulated genes by differential-display PCR. International Journal of Neuropsychopharmacology, 2001, 4, 65-74.	2.1	25
92	Decreased Brain-Derived Neurotrophic Factor in Older Adults with Bipolar Disorder. American Journal of Geriatric Psychiatry, 2016, 24, 596-601.	1.2	23
93	DNA redox modulations and global DNA methylation in bipolar disorder: Effects of sex, smoking and illness state. Psychiatry Research, 2018, 261, 589-596.	3.3	22
94	Getting to wellness: The potential of the athletic model of marginal gains for the treatment of bipolar disorder. Australian and New Zealand Journal of Psychiatry, 2015, 49, 1207-1214.	2.3	21
95	Alterations in phosphorylated cAMP response element-binding protein (pCREB) signaling: an endophenotype of lithium-responsive bipolar disorder?. Bipolar Disorders, 2013, 15, 824-831.	1.9	20
96	Mood stabilizing drugs lamotrigine and olanzapine increase expression and activity of glutathione s-transferase in primary cultured rat cerebral cortical cells. Neuroscience Letters, 2009, 455, 70-73.	2.1	19
97	Abstinence from repeated amphetamine treatment induces depressive-like behaviors and oxidative damage in rat brain. Psychopharmacology, 2013, 227, 605-614.	3.1	19
98	Combined treatment: impact of optimal psychotherapy and medication in bipolar disorder. Bipolar Disorders, 2015, 17, 86-96.	1.9	19
99	A Longitudinal Study of the Relationships Between Mood Symptoms, Body Mass Index, and Serum Adipokines in Bipolar Disorder. Journal of Clinical Psychiatry, 2017, 78, 441-448.	2.2	18
100	Chronic Lithium Treatment Inhibits Pilocarpine-Induced Mossy Fiber Sprouting in Rat Hippocampus. Neuropsychopharmacology, 2003, 28, 1448-1453.	5.4	17
101	Dentate gyrusâ^'cornu ammonis (CA) 4 volume is decreased and associated with depressive episodes and lipid peroxidation in bipolar <scp>II</scp> disorder: Longitudinal and crossâ€sectional analyses. Bipolar Disorders, 2016, 18, 657-668.	1.9	17
102	The evolution of CANMAT Bipolar Disorder Guidelines: past, present, and future. Bipolar Disorders, 2013, 15, 58-60.	1.9	14
103	Vitis labrusca extract effects on cellular dynamics and redox modulations in a SH-SY5Y neuronal cell model: A similar role to lithium. Neurochemistry International, 2014, 79, 12-19.	3.8	13
104	Regional distribution of guanine nucleotide binding proteins (Gs and Gi Î±) in human brain: correlation with adenylyl cyclase activity. Neurochemistry International, 1993, 22, 285-291.	3.8	12
105	What exactly is a mood stabilizer?. Journal of Psychiatry and Neuroscience, 2004, 29, 87-8.	2.4	12
106	Inflammatory markers, brain-derived neurotrophic factor, and the symptomatic course of adolescent bipolar disorder: A prospective repeated-measures study. Brain, Behavior, and Immunity, 2022, 100, 278-286.	4.1	12
107	Course of Illness, Hippocampal Function, and Hippocampal Volume in Major Depression. Focus (American Psychiatric Publishing), 2005, 3, 146-155.	0.8	10
108	Insulin-like growth factor binding protein-2 expression is decreased by lithium. NeuroReport, 2006, 17, 897-901.	1.2	10

#	Article	IF	Citations
109	Elevated Stimulatory and Reduced Inhibitory G Protein ? Subunits in Cerebellar Cortex of Patients with Dominantly Inherited Olivopontocerebellar Atrophy. Journal of Neurochemistry, 1993, 60, 1816-1820.	3.9	9
110	Psychiatric Consultation in the Eastern Canadian Arctic: III. Mental Health Issues in Inuit Women in the Eastern Arctic. Canadian Journal of Psychiatry, 1993, 38, 32-35.	1.9	9
111	Three visions of doctoring: a Gadamerian dialogue. Advances in Health Sciences Education, 2019, 24, 403-412.	3.3	9
112	Number of episodes and antidepressant response in major depression. International Journal of Neuropsychopharmacology, 1999, 2, 111-113.	2.1	8
113	Regulators of mitochondrial complex I activity: A review of literature and evaluation in postmortem prefrontal cortex from patients with bipolar disorder. Psychiatry Research, 2016, 236, 148-157.	3.3	8
114	Prevalence and health care costs of mitochondrial disease in Ontario, Canada: A population-based cohort study. PLoS ONE, 2022, 17, e0265744.	2.5	8
115	Regulation of molecular chaperone GRP78 by mood stabilizing drugs. Clinical Neuroscience Research, 2004, 4, 281-288.	0.8	7
116	Glutathione-mediated effects of lithium in decreasing protein oxidation induced by mitochondrial complex I dysfunction. Journal of Neural Transmission, 2015, 122, 741-746.	2.8	6
117	Psychiatric Consultation in the Eastern Canadian Arctic: I. Development and Evolution of the Baffin Psychiatric Consultation Service. Canadian Journal of Psychiatry, 1993, 38, 23-27.	1.9	5
118	â€œDouble bipolar disorderâ€• A separate entity?. Depression, 1994, 2, 223-225.	0.6	5
119	Prior antidepressant treatment does not have an impact on response to desipramine treatment in major depression. Biological Psychiatry, 1995, 38, 410-412.	1.3	5
120	Signal Transduction Pathways in the Pathophysiology of Bipolar Disorder. Current Topics in Behavioral Neurosciences, 2010, 5, 139-165.	1.7	3
121	What is the best treatment for bipolar depression?. Journal of Psychiatry and Neuroscience, 2008, 33, 487-8.	2.4	3
122	Platelet endogenous adenosine 5â€²-diphosphate ribosylation in drug-free and lithium-treated subjects with bipolar disorder. Biological Psychiatry, 1997, 42, 413-415.	1.3	2
123	Structural plasticity and neuronal resilience: are these targets for mood stabilizers and antidepressants in the treatment of bipolar disorder?. Bipolar Disorders, 2002, 4, 77-79.	1.9	1
124	Applying Molecular Approaches to Understand the Etiology and Treatment of Bipolar Disorder. Canadian Journal of Psychiatry, 2007, 52, 751-752.	1.9	1
125	Response to commentaries on the Canadian Network for Mood and Anxiety Treatments/International Society for Bipolar Disorders 2013 updated Bipolar Disorder Guidelines. Bipolar Disorders, 2013, 15, 338-339.	1.9	1
126	Understanding the neurobiology of bipolar depression. , 2009, , 77-94.		1

#	Article	IF	Citations
127	Understanding the Neurobiology of Bipolar Depression. Milestones in Drug Therapy, 2016, , 93-114.	0.1	1
128	Molecular Abnormalities in Brains of Depressed Patients. Neuroscientist, 2000, 6, 401-410.	3.5	0
129	Assessment of Patients with Bipolar Disorder. , 2006, , 51-69.		0
130	Marcadores de estrÃ©s oxidativo en el trastorno bipolar: un metaanÃ¡lisis. Psiquiatria Biologica, 2009, 16, 60-69.	0.1	0
131	Reply. Acta Psychiatrica Scandinavica, 2015, 131, 397-398.	4.5	0